Psoriatic Arthritis Market, By Drug Class (DMARD, NSAIDs, Biologics, and Others), By Product Type (OTC and Prescriptions), By Route of Administration (Oral, Topical, and Injectable), and By Region - Trends, Analysis, and Forecast till 2029

Psoriatic arthritis prevalence is rising, and treatment has advanced.

Patients with psoriatic arthritis are growing annually. A study published in the International Journal of Clinical Rheumatology states that 15% of patients with psoriasis may have undetected psoriatic arthritis. Psoriatic arthritis is classified as a subtype of spondyloarthritis, which affects 42% of people with psoriasis. Rising drug prices, rising cases, and rising diagnoses drive the psoriatic arthritis market. The field of personalized medicine has advanced in the last many years. It cannot precisely target the tissue, region, or place that requires treatment.

Side Effects of the Medication

The development of new drugs has greatly benefited treatment. These very sophisticated medications do, however, have specific negative health impacts on people. Think about NSAIDs. While stomach discomfort, cardiac issues, liver and kidney damage, and reduced inflammation are possible adverse effects of nonsteroidal anti-inflammatory medicines (NSAIDs), these medications can also relieve pain. Furthermore, DMARDs, or disease-modifying anti-rheumatic drugs, can stop irreversible damage to joints and other tissues by delaying the course of psoriatic arthritis. Severe lung infections, bone marrow suppression, and liver damage are possible adverse effects; however, they can vary. The market may be discouraged by this.